Longeveron (LGVN) Intangibles (2020 - 2026)
Longeveron (LGVN) recorded quarterly Intangibles of $3.9 million in Q1 2026, up 0.52% quarter-over-quarter from $3.9 million in Q4 2025, and up 70.36% on a YoY basis from $2.3 million in Q1 2025.
Longeveron (LGVN) Intangibles (2020 - 2026) Analysis & Trends
Longeveron's Intangibles history runs 7 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- In Q1 2026, Intangibles rose 70.36% year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $3.9 million (up 70.36% YoY), while the FY2025 annual figure was $3.9 million, up 61.72% from the prior year.
- Intangibles was $3.9 million for Q1 2026 at Longeveron, up from $3.9 million in the prior quarter.
- In the past five years, Intangibles ranged from a high of $3.9 million in Q1 2026 to a low of $1.2 million in Q2 2023.
- Historically, Intangibles has averaged $2.7 million across 5 years, with a median of $2.4 million in 2023.
- The sharpest annual moves came in 2023 and 2024: Intangibles tumbled 57.49% in 2023, then jumped 88.84% in 2024.
- A 5-year view of Intangibles shows it stood at $2.4 million in 2022, then soared by 32.67% to $3.2 million in 2023, then declined by 24.87% to $2.4 million in 2024, then jumped by 61.72% to $3.9 million in 2025, then rose by 0.52% to $3.9 million in 2026.
- The last three Intangibles figures came in at $3.9 million (Q1 2026), $3.9 million (Q4 2025), and $2.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4.41 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 30.30 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 418.50 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 7.73 Mn |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 3.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.90 Mn |
| Dec 31, 2025 | 3.88 Mn |
| Sep 30, 2025 | 2.31 Mn |
| Jun 30, 2025 | 2.32 Mn |
| Mar 31, 2025 | 2.29 Mn |
| Dec 31, 2024 | 2.40 Mn |
| Sep 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 2.35 Mn |
| Mar 31, 2024 | 3.23 Mn |
| Dec 31, 2023 | 3.20 Mn |
| Sep 30, 2023 | 2.54 Mn |
| Jun 30, 2023 | 1.25 Mn |
| Mar 31, 2023 | 2.43 Mn |
| Dec 31, 2022 | 2.41 Mn |
| Sep 30, 2022 | 3.00 Mn |
| Jun 30, 2022 | 2.93 Mn |
| Mar 31, 2022 | 2.88 Mn |
| Dec 31, 2021 | 2.81 Mn |
| Sep 30, 2021 | 2.78 Mn |
| Jun 30, 2021 | 2.75 Mn |